117 related articles for article (PubMed ID: 8430625)
21. [The cholesterol hypothesis has been proved true at last].
Huttunen J
Duodecim; 1995; 111(5):385-6. PubMed ID: 8674438
[No Abstract] [Full Text] [Related]
22. Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
Guptha S
Curr Opin Lipidol; 1995 Oct; 6(5):251-3. PubMed ID: 8520845
[No Abstract] [Full Text] [Related]
23. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S).
Lancet; 1995 May; 345(8960):1274-5. PubMed ID: 7746058
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
[TBL] [Abstract][Full Text] [Related]
26. Statin therapy in clinical practice: new developments.
Shepherd J
Curr Opin Lipidol; 1995 Oct; 6(5):254-5. PubMed ID: 8520846
[No Abstract] [Full Text] [Related]
27. The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study.
Dujovne CA
Am J Cardiol; 1997 May; 79(10):1387-8. PubMed ID: 9165163
[TBL] [Abstract][Full Text] [Related]
28. [The Scandinavian Simvastatin Survival Study: the clinical consequences].
Larsen ML
Rev Esp Cardiol; 1995; 48 Suppl 5():39-42. PubMed ID: 7494939
[TBL] [Abstract][Full Text] [Related]
29. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Ziegler O; Drouin P
Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
[TBL] [Abstract][Full Text] [Related]
32. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
Teo KK; Burton JR; Buller C; Plante S; Yokoyama S; Montague TJ
Can J Cardiol; 1997 Jun; 13(6):591-9. PubMed ID: 9215232
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
Am J Cardiol; 1993 Jun; 71(16):1408-14. PubMed ID: 8517385
[TBL] [Abstract][Full Text] [Related]
34. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.
Arnadottir M; Eriksson LO; Germershausen JI; Thysell H
Nephron; 1994; 68(1):57-62. PubMed ID: 7991041
[TBL] [Abstract][Full Text] [Related]
35. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).
Lancet; 1994 Sep; 344(8923):633-8. PubMed ID: 7864934
[TBL] [Abstract][Full Text] [Related]
36. Scandinavian simvastatin study (4S).
Wright RA; Flapan AD
Lancet; 1994 Dec 24-31; 344(8939-8940):1765; author reply 1767-8. PubMed ID: 7997011
[No Abstract] [Full Text] [Related]
37. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).
Strandberg TE; Pyörälä K; Cook TJ; Wilhelmsen L; Faergeman O; Thorgeirsson G; Pedersen TR; Kjekshus J;
Lancet; 2004 Aug 28-Sep 3; 364(9436):771-7. PubMed ID: 15337403
[TBL] [Abstract][Full Text] [Related]
38. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
Haffner SM; Alexander CM; Cook TJ; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
Arch Intern Med; 1999 Dec 13-27; 159(22):2661-7. PubMed ID: 10597756
[TBL] [Abstract][Full Text] [Related]
39. Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study.
Pedersen TR; Jahnsen KE; Vatn S; Semb AG; Kontny F; Zalmai A; Nerdrum T
Clin Ther; 2000 Aug; 22(8):949-60. PubMed ID: 10972631
[TBL] [Abstract][Full Text] [Related]
40. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl.
Aronow WS
Am J Cardiol; 1998 Sep; 82(5):668-9, A6, A8. PubMed ID: 9732899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
